These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 28042021

  • 1. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation.
    Hosokai R, Masuko M, Shibasaki Y, Saitoh A, Furukawa T, Imai C.
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):606-611. PubMed ID: 28042021
    [Abstract] [Full Text] [Related]

  • 2. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H, Bao X, Wu X, Tang X, Wang M, Wu D, He J.
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [Abstract] [Full Text] [Related]

  • 3. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U, Dalva K, Gungor F, Ustun C, Beksac M.
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA, Jafari D, Mahmoodi M, Alimoghaddam K, Ostadali M, Talebzadeh Bonakdar A, Foma AM, Yekaninejad MS, Amirzargar AA.
    Turk J Med Sci; 2018 Aug 16; 48(4):794-804. PubMed ID: 30119155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Masood Khan F.
    PLoS One; 2016 Aug 16; 11(6):e0158242. PubMed ID: 27341514
    [Abstract] [Full Text] [Related]

  • 12. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
    Wang H, He Y, Zhai WJ, Wang M, Zhou Z, Zhao YX, Feng SZ, Han MZ.
    Swiss Med Wkly; 2013 Aug 16; 143():w13717. PubMed ID: 23299929
    [Abstract] [Full Text] [Related]

  • 13. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
    Mansouri M, Villard J, Ramzi M, Alavianmehr A, Farjadian S.
    Hum Immunol; 2020 Jun 16; 81(6):285-292. PubMed ID: 32199702
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE.
    Biol Blood Marrow Transplant; 2016 Jul 16; 22(7):1290-1298. PubMed ID: 27090958
    [Abstract] [Full Text] [Related]

  • 18. Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes.
    Kanda J, Ikegame K, Fuji S, Kurokawa M, Kanamori H, Fukuda T, Ohashi K, Ishikawa J, Ogawa H, Inoue M, Ichinohe T, Atsuta Y, Kanda Y, HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant; 2016 Nov 16; 22(11):2031-2037. PubMed ID: 27492794
    [Abstract] [Full Text] [Related]

  • 19. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.
    Michaelis SU, Mezger M, Bornhäuser M, Trenschel R, Stuhler G, Federmann B, Oevermann L, Kanz L, Handgretinger R, Bethge WA.
    Ann Hematol; 2014 Sep 16; 93(9):1579-86. PubMed ID: 24771045
    [Abstract] [Full Text] [Related]

  • 20. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
    Duan LN, Han HX, Liu J, Yan HM, Zhu L, Xue M, Ding L, Zhu PY, Wang HX, Ji SQ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug 16; 15(4):809-15. PubMed ID: 17708809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.